NEXENTIS TECHNOLOGIES INC. Severance Costs
NEXENTIS TECHNOLOGIES INC. (NXTS) reported Severance Costs of $32.27 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2023-03-27
- NEXENTIS TECHNOLOGIES INC. severance costs for fiscal 2022 was $32.27K, a 43.38% increase from fiscal 2021.
- NEXENTIS TECHNOLOGIES INC. severance costs for fiscal 2021 was $22.51K, a 203.37% increase from fiscal 2020.
- NEXENTIS TECHNOLOGIES INC. severance costs for fiscal 2020 was $7.42K, a 69.09% decline from fiscal 2019.
- NEXENTIS TECHNOLOGIES INC. severance costs for fiscal 2019 was $24.00K, a 141.96% increase from fiscal 2018.
| Period end | Severance Costs 12 month | Severance Costs 12 month as first filed |
|---|---|---|
| 2022-12-31 | $32.27K 10-K · filed 2023-03-27 | |
| 2021-12-31 | $22.51K 10-K · filed 2023-03-27 | $6.82K 10-K · filed 2022-03-31 |
| 2020-12-31 | $7.42K 10-K · filed 2022-03-31 | |
| 2019-12-31 | $24.00K 10-K · filed 2021-03-29 | |
| 2018-12-31 | $9.92K 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |